AGENDA • Business Overview – Gary S. Jacob • Financial Update – Gary Gemignani • Launch Update –Troy Hamilton • Closing Remarks – Gary Jacob • Q&A Portion
Sales force of ~ 250 educating ~ 27,000 prescribers ü Over 360,000 sample packs distributed to field to date ü ~ 430 peer-to-peer speaker programs, > 6000 attendees ü Launched comprehensive HCP media plan ü DDW 2017 –significant promotional presence; 6 abstracts (two posters of distinction, one oral presentation)
ü Trulance Campaign: ? Point of Care Promotion: ~ 20,000 offices ? Web Sponsorships/Display Ads: > 245,000,000 impressions ? Search Engine Marketing: > 403,000 clicks ? Trulance.com visits: > 615,000 for consumer site ü Confront Constipation Campaign: ? Disease awareness initiative ? 33 original media placements ? > 310,000,000 media impressions ? > 95,000 Emoji App downloads
Liav Abraham Great. And then just perhaps a [Indiscernible] question on your comments. You mentioned that R&D spend will be going down. What plans do you have for lifecycle management of TRULANCE? I do understand that the molecule has -- or the drug has a long IP runway. But I'm just interested on any thoughts you have in that regard or should we expect 2032 to be kind of the end of the -- we should expect [Indiscernible] immediately thereafter [Indiscernible] the opportunity to diminish significantly after 2032? Troy Hamilton Hey Liav its Troy. I can answer that question. Obviously, from a lifecycle perspective, we're evaluating several options, I think. Of course, the first one is IBS-C. And that -- it's rather obvious, but also it's very important in terms of how we can enhance our promotion materials and provide additional data to prescribers. But in terms of other options, we are evaluating that and we'll continue to provide updates as we progress with any of those options. But at this time, we're not going to divulge any details in terms of some of those lifecycle options.
News 
Market Data 
Discover 
